Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise
Thus, although much research is focused on defining the direct intrakidney effects of GLP-1 receptor agonists, it is possible that some of the benefits occur indirectly, as a result of GLP-1 receptor agonists ability to improve kidney risk factors, as well as via extrarenal systemic effects of these agents that are not yet fully defined, such as attenuation of low-grade systemic inflammation
The final number of analyzed trials was 19
Per FDA's June 2026 warning letters, "clinically proven" language applied to compounded GLP-1 medications specifically is one of the flagged violation patterns - because the clinical trials that established GLP-1 efficacy tested FDA-approved finished products, not compounded preparations
doi: 10.1371/journal.pone.0083314 [DOI] [PMC free article] [PubMed] [Google Scholar] 184
Does Inno Shred GLP-1 contain artificial ingredients
